{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:24:05Z","timestamp":1791390245656,"version":"4.3.3"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003000","name":"Stichting MS Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ejpn.2020.10.006","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T22:54:00Z","timestamp":1604444040000},"page":"2-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":161,"special_numbering":"C","title":["E.U. paediatric MOG consortium consensus: Part 1 \u2013 Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7990-5894","authenticated-orcid":false,"given":"Arlette L.","family":"Bruijstens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2720-1019","authenticated-orcid":false,"given":"Christian","family":"Lechner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Flet-Berliac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumaran","family":"Deiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6136-4981","authenticated-orcid":false,"given":"Rinze F.","family":"Neuteboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Hemingway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangeline","family":"Wassmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.U. paediatric","family":"Mog consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlette L.","family":"Bruijstens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Maria","family":"Wendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lechner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Breu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Flet-Berliac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali\u00e9nor","family":"de Chalus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Capobianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgi","family":"Laetitia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Hemingway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangeline","family":"Wassmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronny","family":"Wickstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tha\u00eds","family":"Armangue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumaran","family":"Deiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinze F.","family":"Neuteboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejpn.2020.10.006_bib1","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1212\/01.wnl.0000339482.84392.bd","article-title":"Incidence of acquired demyelination of the CNS in Canadian children","volume":"72","author":"Banwell","year":"2009","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.ejpn.2020.10.006_bib2","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.ejpn.2020.10.006_bib3","first-page":"1929","article-title":"Incidence of acquired demyelinating syndromes of the CNS in Dutch children: a nationwide study","volume":"259","author":"Ketelslegers","year":"2012","journal-title":"J.\u00a0Neurol."},{"issue":"3","key":"10.1016\/j.ejpn.2020.10.006_bib4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.spen.2017.08.007","article-title":"The spectrum of inflammatory acquired demyelinating syndromes in children","volume":"24","author":"Neuteboom","year":"2017","journal-title":"Semin. Pediatr. Neurol."},{"issue":"9451","key":"10.1016\/j.ejpn.2020.10.006_bib5","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A\u00a0serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ejpn.2020.10.006_bib6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","article-title":"The spectrum of MOG autoantibody-associated demyelinating diseases","volume":"9","author":"Reindl","year":"2013","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2020.10.006_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0037-1604404","article-title":"MOG spectrum disorders and role of MOG-antibodies in clinical practice","volume":"49","author":"Hennes","year":"2018","journal-title":"Neuropediatrics"},{"issue":"1","key":"10.1016\/j.ejpn.2020.10.006_bib8","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1471-4159.1989.tb10930.x","article-title":"Differential ultrastructural localization of myelin basic protein, myelin\/oligodendroglial glycoprotein, and 2',3'-cyclic nucleotide 3'-phosphodiesterase in the CNS of adult rats","volume":"52","author":"Brunner","year":"1989","journal-title":"J.\u00a0Neurochem."},{"issue":"4","key":"10.1016\/j.ejpn.2020.10.006_bib9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nrn784","article-title":"New concepts in the immunopathogenesis of multiple sclerosis","volume":"3","author":"Hemmer","year":"2002","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejpn.2020.10.006_bib124","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejpn.2020.11.001","article-title":"E.U. paediatric MOG consortium consensus: Part 3 - Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"21","author":"Armangue","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"12","key":"10.1016\/j.ejpn.2020.10.006_bib10","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1177\/1352458514566666","article-title":"Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort","volume":"21","author":"Ketelslegers","year":"2015","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.ejpn.2020.10.006_bib11","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1212\/NXI.0000000000000081","article-title":"Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children","volume":"2","author":"Hacohen","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"9","key":"10.1016\/j.ejpn.2020.10.006_bib12","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","article-title":"Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome","volume":"89","author":"Hennes","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2020.10.006_bib13","article-title":"Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","author":"Waters","year":"2019","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.ejpn.2020.10.006_bib14","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","article-title":"Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination","volume":"15","author":"Ramanathan","year":"2016","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.ejpn.2020.10.006_bib15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejpn.2020.10.006_bib16","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","author":"de Mol","year":"2019","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.ejpn.2020.10.006_bib17","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1212\/WNL.0b013e318228c0b1","article-title":"Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis","volume":"77","author":"Probstel","year":"2011","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ejpn.2020.10.006_bib18","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1001\/archneurol.2011.2956","article-title":"Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis","volume":"69","author":"Rostasy","year":"2012","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2020.10.006_bib19","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1212\/NXI.0000000000000012","article-title":"Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton","volume":"1","author":"Dale","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"10.1016\/j.ejpn.2020.10.006_bib20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S2352-4642(18)30026-9","article-title":"MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study","volume":"2","author":"Fadda","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"issue":"9","key":"10.1016\/j.ejpn.2020.10.006_bib21","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/dmcn.13703","article-title":"Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes","volume":"60","author":"Duignan","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"issue":"3","key":"10.1016\/j.ejpn.2020.10.006_bib22","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","article-title":"Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study","volume":"19","author":"Armangue","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejpn.2020.10.006_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.msard.2019.02.023","article-title":"Clinical characteristics of myelin oligodendrocyte glycoprotein antibody neuromyelitis optica spectrum disorder","volume":"30","author":"Salama","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.ejpn.2020.10.006_bib24","first-page":"845","article-title":"MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein","volume":"265","author":"Baumann","year":"2018","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.ejpn.2020.10.006_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.msard.2018.07.022","article-title":"Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders","volume":"26","author":"Konuskan","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"10.1016\/j.ejpn.2020.10.006_bib26","first-page":"1945","article-title":"MOG antibody-related disorders: common features and uncommon presentations","volume":"264","author":"Cobo-Calvo","year":"2017","journal-title":"J.\u00a0Neurol."},{"issue":"2","key":"10.1016\/j.ejpn.2020.10.006_bib27","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/1352458515587751","article-title":"Clinical and MRI phenotype of children with MOG antibodies","volume":"22","author":"Fernandez-Carbonell","year":"2016","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.ejpn.2020.10.006_bib28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11940-019-0541-x","article-title":"Treatment approaches for MOG-ab-associated demyelination in children","volume":"21","author":"Hacohen","year":"2019","journal-title":"Curr. Treat. Options Neurol."},{"issue":"2","key":"10.1016\/j.ejpn.2020.10.006_bib29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1212\/01.wnl.0000314832.24682.c6","article-title":"CNS aquaporin-4 autoimmunity in children","volume":"71","author":"McKeon","year":"2008","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ejpn.2020.10.006_bib30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/jnnp-2014-308346","article-title":"Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein","volume":"86","author":"Baumann","year":"2015","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"9 Suppl 2","key":"10.1016\/j.ejpn.2020.10.006_bib31","first-page":"S67","article-title":"Pediatric acquired CNS demyelinating syndromes: features associated with multiple sclerosis","volume":"87","author":"Hintzen","year":"2016","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.ejpn.2020.10.006_bib32","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/jnnp-2015-311743","article-title":"Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease","volume":"87","author":"Lechner","year":"2016","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"11","key":"10.1016\/j.ejpn.2020.10.006_bib33","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"Lopez-Chiriboga","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ejpn.2020.10.006_bib34","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.pediatrneurol.2018.03.003","article-title":"Clinical characteristics of pediatric optic neuritis with myelin oligodendrocyte glycoprotein seropositive: a cohort study","volume":"83","author":"Chen","year":"2018","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ejpn.2020.10.006_bib35","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.msard.2018.11.026","article-title":"Unique characteristics of optical coherence tomography (OCT) results and visual acuity testing in myelin oligodendrocyte glycoprotein (MOG) antibody positive pediatric patients","volume":"28","author":"Narayan","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.ejpn.2020.10.006_bib36","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/bjophthalmol-2018-312399","article-title":"Clinical characteristics and prognosis of myelin oligodendrocyte glycoprotein antibody-seropositive paediatric optic neuritis in China","volume":"103","author":"Song","year":"2019","journal-title":"Br. J. Ophthalmol."},{"issue":"12","key":"10.1016\/j.ejpn.2020.10.006_bib37","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"issue":"21","key":"10.1016\/j.ejpn.2020.10.006_bib38","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2020.10.006_bib39","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jneuroim.2018.05.014","article-title":"Different features between pediatric-onset and adult-onset patients who are seropositive for MOG-IgG: a multicenter study in South China","volume":"321","author":"Chen","year":"2018","journal-title":"J.\u00a0Neuroimmunol."},{"issue":"2","key":"10.1016\/j.ejpn.2020.10.006_bib40","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"17","key":"10.1016\/j.ejpn.2020.10.006_bib41","doi-asserted-by":"crossref","first-page":"7990","DOI":"10.1073\/pnas.90.17.7990","article-title":"Myelin\/oligodendrocyte glycoprotein is a member of a subset of the immunoglobulin superfamily encoded within the major histocompatibility complex","volume":"90","author":"Pham-Dinh","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.ejpn.2020.10.006_bib42","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/1352458510390068","article-title":"Disease course and outcome of acute disseminated encephalomyelitis is more severe in adults than in children","volume":"17","author":"Ketelslegers","year":"2011","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.ejpn.2020.10.006_bib43","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejpn.2016.08.014","article-title":"Evolution of MRI abnormalities in paediatric acute disseminated encephalomyelitis","volume":"21","author":"Wong","year":"2017","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"9 Suppl 2","key":"10.1016\/j.ejpn.2020.10.006_bib44","first-page":"S38","article-title":"Acute disseminated encephalomyelitis: updates on an inflammatory CNS syndrome","volume":"87","author":"Pohl","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2020.10.006_bib45","doi-asserted-by":"crossref","DOI":"10.1111\/dmcn.14594","article-title":"Risk factors for academic difficulties in children with myelin oligodendrocyte glycoprotein antibody-associated acute demyelinating syndromes","author":"Deiva","year":"2020","journal-title":"Dev. Med. Child Neurol."},{"issue":"3","key":"10.1016\/j.ejpn.2020.10.006_bib46","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/1352458518823486","article-title":"Early predictors of epilepsy and subsequent relapse in children with acute disseminated encephalomyelitis","volume":"26","author":"Rossor","year":"2020","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.ejpn.2020.10.006_bib47","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/ICU.0000000000000607","article-title":"Update on pediatric optic neuritis","volume":"30","author":"Lock","year":"2019","journal-title":"Curr. Opin. Ophthalmol."},{"issue":"12","key":"10.1016\/j.ejpn.2020.10.006_bib48","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/dmcn.13757","article-title":"Retinal nerve fibre layer thinning is associated with worse visual outcome after optic neuritis in children with a relapsing demyelinating syndrome","volume":"60","author":"Eyre","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"issue":"4","key":"10.1016\/j.ejpn.2020.10.006_bib49","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.ejpn.2020.10.006_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpn.2020.04.002","article-title":"High association of MOG-IgG antibodies in children with bilateral optic neuritis","author":"Wendel","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2020.10.006_bib51","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/WCO.0000000000000766","article-title":"Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis","volume":"33","author":"Chen","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.ejpn.2020.10.006_bib52","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jns.2019.03.014","article-title":"Clinical characteristics and outcomes of myelin oligodendrocyte glycoprotein antibody-seropositive optic neuritis in varying age groups: a cohort study in China","volume":"400","author":"Song","year":"2019","journal-title":"J.\u00a0Neurol. Sci."},{"issue":"1","key":"10.1016\/j.ejpn.2020.10.006_bib53","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s12974-018-1335-x","article-title":"Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies","volume":"15","author":"Lee","year":"2018","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.ejpn.2020.10.006_bib54","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am. J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.ejpn.2020.10.006_bib55","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/jnnp-2014-310206","article-title":"MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study","volume":"87","author":"Akaishi","year":"2016","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejpn.2020.10.006_bib56","doi-asserted-by":"crossref","first-page":"104319","DOI":"10.1016\/j.neuint.2018.10.016","article-title":"Clinical spectrum of inflammatory central nervous system demyelinating disorders associated with antibodies against myelin oligodendrocyte glycoprotein","volume":"130","author":"Akaishi","year":"2019","journal-title":"Neurochem. Int."},{"issue":"6","key":"10.1016\/j.ejpn.2020.10.006_bib57","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1212\/NXI.0000000000000163","article-title":"Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS","volume":"2","author":"Kim","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.ejpn.2020.10.006_bib58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jneuroim.2018.09.011","article-title":"Retinal nerve fiber layer thickness in optic neuritis with MOG antibodies: a systematic review and meta-analysis","volume":"325","author":"Peng","year":"2018","journal-title":"J.\u00a0Neuroimmunol."},{"issue":"3","key":"10.1016\/j.ejpn.2020.10.006_bib59","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.ejpn.2020.10.006_bib60","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ejpn.2020.10.006_bib61","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.ejpn.2020.10.006_bib62","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1212\/WNL.0000000000001179","article-title":"Acute idiopathic transverse myelitis in children: early predictors of relapse and disability","volume":"84","author":"Deiva","year":"2015","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ejpn.2020.10.006_bib63","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejpn.2009.12.002","article-title":"Acquired transverse myelopathy in children in the United Kingdom--a 2 year prospective study","volume":"14","author":"De Goede","year":"2010","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"2","key":"10.1016\/j.ejpn.2020.10.006_bib64","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ejpn.2020.10.006_bib65","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/ene.12898","article-title":"Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in The Netherlands","volume":"23","author":"van Pelt","year":"2016","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2020.10.006_bib66","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J.\u00a0Neuroinflammation"},{"issue":"17","key":"10.1016\/j.ejpn.2020.10.006_bib67","doi-asserted-by":"crossref","first-page":"e1642","DOI":"10.1212\/WNL.0000000000006392","article-title":"Area postrema syndrome: frequency, criteria, and severity in AQP4-IgG-positive NMOSD","volume":"91","author":"Shosha","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ejpn.2020.10.006_bib68","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12974-016-0719-z","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement - frequency, presentation and outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J.\u00a0Neuroinflammation"},{"issue":"2","key":"10.1016\/j.ejpn.2020.10.006_bib69","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1212\/WNL.0000000000008786","article-title":"Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgG-associated disorders (MOGAD)?","volume":"94","author":"Kunchok","year":"2020","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.ejpn.2020.10.006_bib70","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1177\/1352458510382324","article-title":"Neuromyelitis optica: a demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytes","volume":"16","author":"Parratt","year":"2010","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.ejpn.2020.10.006_bib71","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s12264-019-00375-8","article-title":"Myelin oligodendrocyte glycoprotein-IgG contributes to oligodendrocytopathy in the presence of complement, distinct from astrocytopathy induced by AQP4-IgG","volume":"35","author":"Fang","year":"2019","journal-title":"Neurosci Bull"},{"issue":"1","key":"10.1016\/j.ejpn.2020.10.006_bib72","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/nyas.12794","article-title":"Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later","volume":"1366","author":"Pittock","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"3","key":"10.1016\/j.ejpn.2020.10.006_bib73","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000702","article-title":"HLA association in MOG-IgG- and AQP4-IgG-related disorders of the CNS in the Dutch population","volume":"7","author":"Bruijstens","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.ejpn.2020.10.006_bib74","article-title":"MOG-antibody-associated disease is different from MS and NMOSD and should be considered as a distinct disease entity - Yes","author":"Leite","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.ejpn.2020.10.006_bib75","article-title":"MOG-antibody-associated disease is different from MS and NMOSD and should be classified as a distinct disease entity - Commentary","author":"Fujihara","year":"2019","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.ejpn.2020.10.006_bib76","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/WCO.0000000000000681","article-title":"Clinical spectrum of central nervous system myelin oligodendrocyte glycoprotein autoimmunity in adults","volume":"32","author":"Cobo-Calvo","year":"2019","journal-title":"Curr. Opin. Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2020.10.006_bib77","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1212\/NXI.0000000000000062","article-title":"Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?","volume":"2","author":"Zamvil","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"10.1016\/j.ejpn.2020.10.006_bib78","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrneurol.2016.9","article-title":"Demyelinating disease: NMO spectrum disorders: clinical or molecular classification?","volume":"12","author":"Pittock","year":"2016","journal-title":"Nat. Rev. Neurol."},{"issue":"21","key":"10.1016\/j.ejpn.2020.10.006_bib79","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1212\/WNL.0000000000005619","article-title":"Time to separate MOG-Ab-associated disease from AQP4-Ab-positive neuromyelitis optica spectrum disorder","volume":"90","author":"Hacohen","year":"2018","journal-title":"Neurology"},{"issue":"415","key":"10.1016\/j.ejpn.2020.10.006_bib80","article-title":"Epidemiology of pediatric NMOSD in Germany and Austria","volume":"11","author":"Lechner","year":"2020","journal-title":"Front. Neurol."},{"issue":"3","key":"10.1016\/j.ejpn.2020.10.006_bib81","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1212\/WNL.0000000000004117","article-title":"Diagnostic algorithm for relapsing acquired demyelinating syndromes in children","volume":"89","author":"Hacohen","year":"2017","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ejpn.2020.10.006_bib82","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol"},{"issue":"14","key":"10.1016\/j.ejpn.2020.10.006_bib83","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1177\/1352458516631038","article-title":"Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): extending the spectrum of MOG antibody positive diseases","volume":"22","author":"Baumann","year":"2016","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.ejpn.2020.10.006_bib84","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1177\/1352458512466317","article-title":"Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients","volume":"19","author":"Huppke","year":"2013","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.ejpn.2020.10.006_bib85","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/ene.13602","article-title":"Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome","volume":"25","author":"Wong","year":"2018","journal-title":"Eur. J. Neurol."},{"issue":"4","key":"10.1016\/j.ejpn.2020.10.006_bib86","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1212\/NXI.0000000000000131","article-title":"Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis","volume":"2","author":"Chalmoukou","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"10.1016\/j.ejpn.2020.10.006_bib87","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1212\/NXI.0000000000000040","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis","volume":"1","author":"Ramanathan","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"10.1016\/j.ejpn.2020.10.006_bib88","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/jnnp-2016-315094","article-title":"Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies","volume":"88","author":"Fujimori","year":"2017","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.ejpn.2020.10.006_bib89","first-page":"2481","article-title":"Unilateral cortical FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis with Seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome","volume":"266","author":"Budhram","year":"2019","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.ejpn.2020.10.006_bib90","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fneur.2020.00031","article-title":"A\u00a0fulminant case of demyelinating encephalitis with extensive cortical involvement associated with anti-MOG antibodies","volume":"11","author":"Hochmeister","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejpn.2020.10.006_bib91","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jns.2018.06.028","article-title":"The pathological features of MOG antibody-positive cerebral cortical encephalitis as a new spectrum associated with MOG antibodies: a case report","volume":"392","author":"Ikeda","year":"2018","journal-title":"J.\u00a0Neurol. Sci."},{"issue":"1","key":"10.1016\/j.ejpn.2020.10.006_bib92","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s12883-017-0971-6","article-title":"MOG antibody seropositivity in a patient with encephalitis: beyond the classical syndrome","volume":"17","author":"Mariotto","year":"2017","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ejpn.2020.10.006_bib93","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.msard.2018.07.028","article-title":"A\u00a0case of anti-MOG antibody-positive unilaterally dominant meningoencephalitis followed by longitudinally extensive transverse myelitis","volume":"25","author":"Sugimoto","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.ejpn.2020.10.006_bib94","doi-asserted-by":"crossref","first-page":"102033","DOI":"10.1016\/j.msard.2020.102033","article-title":"Self-remitting cerebral cortical encephalitis associated with myelin oligodendrocyte glycoprotein antibody mimicking acute viral encephalitis: a case report","volume":"41","author":"Otani","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.ejpn.2020.10.006_bib95","first-page":"1","article-title":"Unilateral cerebral cortical encephalitis with epilepsy: a possible special phenotype of MOG antibody-associated disorders","author":"Tao","year":"2020","journal-title":"Int. J. Neurosci."},{"issue":"2","key":"10.1016\/j.ejpn.2020.10.006_bib96","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1212\/NXI.0000000000000322","article-title":"MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy","volume":"4","author":"Ogawa","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.ejpn.2020.10.006_bib97","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/ene.13790","article-title":"Encephalitis is an important clinical component of myelin oligodendrocyte glycoprotein antibody associated demyelination: a single-center cohort study in Shanghai, China","volume":"26","author":"Wang","year":"2019","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2020.10.006_bib98","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamaneurol.2017.3196","article-title":"Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease","volume":"75","author":"Hamid","year":"2018","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.ejpn.2020.10.006_bib99","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A\u00a0clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.ejpn.2020.10.006_bib100","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1177\/1352458519837705","article-title":"MOG antibody-associated encephalomyelitis\/encephalitis","volume":"25","author":"Salama","year":"2019","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.ejpn.2020.10.006_bib101","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000731","article-title":"Clinical and imaging features of children with autoimmune encephalitis and MOG antibodies","volume":"7","author":"Wegener-Panzer","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"8","key":"10.1016\/j.ejpn.2020.10.006_bib102","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/cid\/cit458","article-title":"Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium","volume":"57","author":"Venkatesan","year":"2013","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.ejpn.2020.10.006_bib103","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jpeds.2012.10.011","article-title":"Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients","volume":"162","author":"Armangue","year":"2013","journal-title":"J.\u00a0Pediatr."},{"issue":"3","key":"10.1016\/j.ejpn.2020.10.006_bib104","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ana.24117","article-title":"Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis","volume":"75","author":"Titulaer","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejpn.2020.10.006_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2019.577124","article-title":"Overlapping autoimmune syndrome: a case of concomitant anti-NMDAR encephalitis and myelin oligodendrocyte glycoprotein (MOG) antibody disease","volume":"339","author":"Perez","year":"2020","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.ejpn.2020.10.006_bib106","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.msard.2018.01.007","article-title":"Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis","volume":"20","author":"Fan","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.ejpn.2020.10.006_bib107","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jneuroim.2018.03.019","article-title":"An unusual case of anti-MOG CNS demyelination with concomitant mild anti-NMDAR encephalitis","volume":"320","author":"Zhou","year":"2018","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.ejpn.2020.10.006_bib108","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jneuroim.2018.12.003","article-title":"A\u00a0case of recurrent MOG antibody positive bilateral optic neuritis and anti-NMDAR encephalitis: different biological evolution of the two associated antibodies","volume":"328","author":"Rojc","year":"2019","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.ejpn.2020.10.006_bib109","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.msard.2019.08.002","article-title":"Repeated anti-N-methyl-D-aspartate receptor encephalitis coexisting with anti-myelin oligodendrocyte glycoprotein antibody-associated diseases: a case report","volume":"35","author":"Aoe","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.ejpn.2020.10.006_bib110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.msard.2018.12.017","article-title":"A\u00a0rare concurrence: antibodies against Myelin Oligodendrocyte Glycoprotein and N-methyl-d-aspartate receptor in a child","volume":"28","author":"Sarigecili","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.ejpn.2020.10.006_bib111","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3389\/fneur.2019.00906","article-title":"Pediatric autoimmune encephalitis: case series from two Chinese tertiary pediatric neurology centers","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejpn.2020.10.006_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102018","article-title":"Clinical analysis of anti-NMDAR encephalitis combined with MOG antibody in children","volume":"42","author":"Hou","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.ejpn.2020.10.006_bib113","doi-asserted-by":"crossref","first-page":"102011","DOI":"10.1016\/j.msard.2020.102011","article-title":"Seizures and myelin oligodendrocyte glycoprotein (MOG) antibodies: two paradigmatic cases and a review of the literature","volume":"41","author":"Foiadelli","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"10.1016\/j.ejpn.2020.10.006_bib114","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/dmcn.14032","article-title":"Isolated seizures during the first episode of relapsing myelin oligodendrocyte glycoprotein antibody-associated demyelination in children","volume":"61","author":"Ramanathan","year":"2019","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ejpn.2020.10.006_bib115","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.msard.2018.12.001","article-title":"Follow-up study on Chinese children with relapsing MOG-IgG-associated central nervous system demyelination","volume":"28","author":"Zhou","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.ejpn.2020.10.006_bib116","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/dmcn.13649","article-title":"Leukodystrophy-like' phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"60","author":"Hacohen","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"issue":"2","key":"10.1016\/j.ejpn.2020.10.006_bib117","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1212\/NXI.0000000000000543","article-title":"Cranial nerve involvement in patients with MOG antibody-associated disease","volume":"6","author":"Cobo-Calvo","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"10.1016\/j.ejpn.2020.10.006_bib118","doi-asserted-by":"crossref","first-page":"e503","DOI":"10.1212\/NXI.0000000000000503","article-title":"MOG antibodies in combined central and peripheral demyelination syndromes","volume":"5","author":"Vazquez Do Campo","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"10.1016\/j.ejpn.2020.10.006_bib119","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0304-3940(03)00899-1","article-title":"Myelin oligodendrocyte glycoprotein is expressed in the peripheral nervous system of rodents and primates","volume":"350","author":"Pagany","year":"2003","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejpn.2020.10.006_bib120","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.msard.2018.02.023","article-title":"New clinical implications of anti-myelin oligodendrocyte glycoprotein antibodies in children with CNS demyelinating diseases","volume":"22","author":"Di Pauli","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"10.1016\/j.ejpn.2020.10.006_bib121","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1212\/01.WNL.0000144352.67102.BC","article-title":"CSF characteristics in early-onset multiple sclerosis","volume":"63","author":"Pohl","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2020.10.006_bib123","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejpn.2020.10.007","article-title":"E.U. paediatric MOG consortium consensus: Part 4 e Outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens","year":"2020","journal-title":"J. Paediatr. Neurol."},{"key":"10.1016\/j.ejpn.2020.10.006_bib126","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejpn.2020.10.002","article-title":"E.U. paediatric MOG consortium consensus: Part 2 - Neuroimaging features of paediatric myelin ligodendrocyte glycoprotein antibodyassociated disorders","volume":"29","author":"Baumann","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.ejpn.2020.10.006_bib125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejpn.2020.10.005","article-title":"E.U. paediatric MOG consortium consensus: Part 5 - Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379820301975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379820301975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:37:51Z","timestamp":1761071871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379820301975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":125,"alternative-id":["S1090379820301975"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2020.10.006","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"E.U. paediatric MOG consortium consensus: Part 1 \u2013 Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2020.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.","name":"copyright","label":"Copyright"}]}}